The sNDA is supported by data from the ASSERT study, which included patients less than 17 years old with genetically confirmed Alagille syndrome.
Your search for Odevixibat returned 4 results
Odevixibat is a potent, once-daily, non-systemic ileal bile acid transport inhibitor.
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of November. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
Bylvay is an oral reversible inhibitor of the ileal bile acid transporter.